Dose-Finding Designs for HIV Studies

DOI10.1111/j.0006-341X.2001.01018.xzbMath1209.62319OpenAlexW2032289930WikidataQ77412020 ScholiaQ77412020MaRDI QIDQ3078854

Michael D. Hughes, John O'Quigley, Terry Fenton

Publication date: 1 March 2011

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1111/j.0006-341x.2001.01018.x

zbMATH Keywords

dose-finding studiescontinual reassessment methodtoxicityphase I trialphase II trialdose escalationefficacy studiesHIV clinical trials

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Related Items

Patient-specific dose finding in seamless phase I/II clinical trials ⋮ Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion ⋮ On generalized multinomial models and joint percentile estimation ⋮ A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes ⋮ Continual reassessment and related dose-finding designs ⋮ Bayesian models and decision algorithms for complex early phase clinical trials ⋮ Bayesian phase I/II adaptively randomized oncology trials with combined drugs ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates ⋮ Dynamic calibration of pharmacokinetic parameters in dose-finding studies ⋮ Adaptive designs for selecting drug combinations based on efficacy-toxicity response ⋮ Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials ⋮ Simple benchmark for complex dose finding studies ⋮ Dose-Finding Based on Efficacy-Toxicity Trade-Offs ⋮ Adaptive designs for dose-finding based on efficacy-toxicity response ⋮ Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers ⋮ Sequential Methods in Multi-Arm Clinical Trials ⋮ Up-and-Down Designs for Selecting the Dose with Maximum Success Probability ⋮ Directed Walk Designs for Dose-Response Problems with Competing Failure Modes ⋮ Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials ⋮ Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios

Cites Work

• Unnamed Item
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Using a one-parameter model to sequentially estimate the root of a regression function.
• Consistency of continual reassessment method under model misspecification
• Miscellanea. A stopping rule for the continual reassessment method
• Continual Reassessment Method: A Likelihood Approach
• Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer